Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity
NCT06427226
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
46
Enrollment
OTHER
Sponsor class
Conditions
Doxorubicin Induced Cardiomyopathy
Breast Cancer
Interventions
DRUG:
Dapagliflozin 10mg Tab
Sponsor
Tanta University